VBI Vaccines Inc. (NASDAQ:VBIV) Short Interest Update

VBI Vaccines Inc. (NASDAQ:VBIV) was the target of a significant decline in short interest during the month of July. As of July 15th, there was short interest totalling 276,900 shares, a decline of 33.6% from the June 30th total of 417,000 shares. Based on an average daily volume of 153,200 shares, the days-to-cover ratio is presently 1.8 days. Approximately 1.1% of the company’s stock are short sold.

VBI Vaccines Stock Down 0.2 %

VBI Vaccines stock traded down $0.00 during midday trading on Monday, hitting $0.56. 31,475 shares of the stock were exchanged, compared to its average volume of 273,378. VBI Vaccines has a 52-week low of $0.45 and a 52-week high of $1.36. The business’s 50-day moving average price is $0.65 and its 200-day moving average price is $0.63.

VBI Vaccines (NASDAQ:VBIV) last released its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.02). The firm had revenue of $1.21 million for the quarter, compared to analysts’ expectations of $2.85 million. VBI Vaccines had a negative return on equity of 525.42% and a negative net margin of 881.79%. Research analysts predict that VBI Vaccines will post -1.23 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of VBI Vaccines in a report on Tuesday, July 23rd. They set a “sell” rating on the stock.

VBI Vaccines Company Profile

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.